- Vyant Bio Inc VYNT and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson’s Disease. Specific deal terms were not disclosed.
- The companies will focus on identifying drug candidates that rescue the PD phenotype through developing disease-linked, clinically- translatable assays and biomarkers.
- The approach will integrate and leverage OrganoTherapeutic’s patient-derived, 3D-organoid disease models derived from induced pluripotent stem cells (iPSCs), Vyant Bio’s iPSC expertise, and its AnalytiX machine learning technology.
- Price Action: VYNT shares are up 36.3% at $1.84 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
